Literature DB >> 26231351

Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study.

Savvas Frangos1, Ioannis P Iakovou2, Robert J Marlowe3, Nicolaos Eftychiou4, Loukia Patsali4, Anna Vanezi4, Androulla Savva4, Vassilis Mpalaris2, Evanthia I Giannoula2.   

Abstract

PURPOSE: We determined the reasons for radioiodine thyroid remnant ablation, and the procedure's necessity based on postsurgical remnant size, in patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma (DTC). We identified key clinicopathological, treatment and remnant characteristics, and factors associated with remnant size in 336 patients with pT1/2, M0 DTC ablated during the period September 2010 to October 2013 at one Cypriot or one Greek referral centre.
METHODS: Clinicopathological/treatment characteristics were compiled from charts. Experienced nuclear medicine physicians rated the numbers/intensities of uptake foci in the thyroid bed on postablation planar scintigrams using scales of 0-4 points and 0-3 points, respectively. The product of these scores was taken as the "remnant score" that ranged from 0 (no remnant) to 12 (multiple remnants, intense uptake).
RESULTS: DTC was predominantly papillary. The median [25th-75th percentile] longest primary tumour diameter was 1.0 cm [0.7-1.5 cm]. Despite favourable histotypes and primary tumour classifications, patients often had preablation characteristics suggesting elevated or uncertain risk: 31.0% of patients (104 of 336) had primary tumour multifocality, 22.0% (74) had confirmed cervical lymph node metastases, 37.2% (125) had unknown nodal status, and 38.1% (128) had antithyroglobulin antibody seropositivity. The median [25th-75th percentile] remnant score was 4 [2-6]; 39.9% of patients (134 of 336) had scores ≥6. For the entire cohort, T or N stages (r ≤ 0.174, P ≤ 0.05) correlated positively with the remnant score in a univariate Spearman analysis. The numbers of patients referred by the surgeon, cervical lymph nodes excised and metastatic nodes excised correlated negatively (r ≤ 0.243, P ≤ 0.038) with the remnant score, and the first two factors independently predicted the remnant score (P ≤ 0.037) in a multivariate analysis.
CONCLUSION: Patients with putatively "low-intermediate-risk" DTC frequently had disease characteristics denoting high or uncertain risk, suggesting that "selective" radioiodine ablation in such patients may seldom be applicable outside international centres of excellence. Proxies for surgeon experience and surgical completeness correlated with remnant number/uptake intensity and may aid ablation-related decision-making.

Entities:  

Keywords:  Clinicopathological; Guidelines; Low-risk DTC; Surgeon experience; Thyroid remnant ablation; Thyroid remnant size

Mesh:

Substances:

Year:  2015        PMID: 26231351     DOI: 10.1007/s00259-015-3124-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

Review 2.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

3.  Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer.

Authors:  Juliana Pereira Almeida; Alvaro Enrique Sanabria; Eduardo Nóbrega Pereira Lima; Luiz Paulo Kowalski
Journal:  Head Neck       Date:  2010-11-10       Impact factor: 3.147

Review 4.  Neck node dissection in thyroid cancer. A review.

Authors:  F Pisello; G Geraci; C Lo Nigro; F Li Volsi; G Modica; C Sciumè
Journal:  G Chir       Date:  2010-03

5.  Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.

Authors:  R Michael Tuttle; Norma Lopez; Rebecca Leboeuf; Shaye M Minkowitz; Ravinder Grewal; Matvey Brokhin; Gal Omry; Steve Larson
Journal:  Thyroid       Date:  2010-03       Impact factor: 6.568

6.  Extent of surgery affects survival for papillary thyroid cancer.

Authors:  Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti; Cord Sturgeon
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

Review 7.  Impact of surgical treatment on outcomes for papillary thyroid cancer.

Authors:  Karl Y Bilimoria; Kyle Zanocco; Cord Sturgeon
Journal:  Adv Surg       Date:  2008

8.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

9.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

Review 10.  Systematic review of clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer.

Authors:  Tsai-Wei Huang; Jun-Hung Lai; Mei-Yi Wu; Shiah-Lian Chen; Chih-Hsiung Wu; Ka-Wai Tam
Journal:  BMC Med       Date:  2013-08-29       Impact factor: 8.775

View more
  8 in total

1.  Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer.

Authors:  Frederik A Verburg; Cumali Aktolun; Arturo Chiti; Savvas Frangos; Luca Giovanella; Martha Hoffmann; Ioannis Iakovou; Jasna Mihailovic; Bernd J Krause; Werner Langsteger; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-17       Impact factor: 9.236

2.  Assessment of the impact of 2015 American Thyroid Association guidelines in management of differentiated thyroid cancer patients.

Authors:  Sayak Choudhury; Archi Agrawal; Gouri Pantvaidya; Sneha Shah; Nilendu Purandare; Ameya Puranik; Venkatesh Rangarajan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-09       Impact factor: 9.236

3.  Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma?

Authors:  Dessislava I Stefanova; Arpita Bose; Timothy M Ullmann; Jessica N Limberg; Brendan M Finnerty; Rasa Zarnegar; Thomas J Fahey; Toni Beninato
Journal:  World J Surg       Date:  2020-02       Impact factor: 3.352

4.  Acknowledging gray areas: 2015 vs. 2009 American Thyroid Association differentiated thyroid cancer guidelines on ablating putatively low-intermediate-risk patients.

Authors:  Savvas Frangos; Ioannis P Iakovou; Robert J Marlowe; Nicolaos Eftychiou; Loukia Patsali; Anna Vanezi; Androulla Savva; Vassilis Mpalaris; Evanthia I Giannoula
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-25       Impact factor: 9.236

Review 5.  Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.

Authors:  Chae Moon Hong; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2018-05-02

6.  Lymph Node Metastasis and Extrathyroidal Extension in Papillary Thyroid Microcarcinoma in Cyprus: Suspicious Subcentimeter Nodules Should Undergo FNA When Multifocality is Suspected.

Authors:  Christos Papaioannou; Demetris Lamnisos; Katerina Kyriacou; Theodoros Lyssiotis; Vasilis Constantinides; Savvas Frangos; Aliki Economides; Panayiotis A Economides
Journal:  J Thyroid Res       Date:  2020-03-24

Review 7.  Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review.

Authors:  Mojtaba Ansari; Mostafa Rezaei Tavirani
Journal:  Iran J Pharm Res       Date:  2022-05-14       Impact factor: 1.962

8.  Radioiodine in Differentiated Thyroid Carcinoma: Do We Need Diagnostic Pre-Ablation Iodine-123 Scintigraphy to Optimize Treatment?

Authors:  Elizabeth J de Koster; Taban Sulaiman; Jaap F Hamming; Abbey Schepers; Marieke Snel; Floris H P van Velden; Lioe-Fee de Geus-Oei; Dennis Vriens
Journal:  Diagnostics (Basel)       Date:  2021-03-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.